United States Veterinary Pain Management Market Is segmented By Drugs (NSAIDs, Opioids), By Route of Administration (Oral, Parenteral, Topical), By Animal (Companion Animal, Farm Animal), By Application (Postoperative Pain, Joint Pain, Cancer, Others), By Distribution Channel (Veterinary Hospitals & Clinics, Pharmacies, Online Pharmacies, Others)and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
The united states veterinary pain management market reached US$ YY million in 2022 and is projected to witness lucrative growth by reaching up to US$ YY million by 2031. The market is growing at a CAGR of 5.10% during the forecast period (2024-2031).
Veterinary pain management refers to the administration of various drugs and drug combinations to animals in order to relieve chronic pain. It entails observing behavioural cues and forecasting the type, severity, and duration of pain. Physical compresses, massages, therapy, rehabilitation, acupuncture, laser therapy, and the administration of therapeutic and antianxiety medications are all part of the treatment. These medications can be taken orally, intravenously, or topically. Changes in housing conditions, diet, and level of interaction with other animals and humans are all part of veterinary pain management. It relieves acute surgical, traumatic, and disease-related pain while also improving the animal's overall health.
Market Scope
|
Metrics |
Details |
|
CAGR |
5.10% |
|
Size Available for Years |
2022-2031 |
|
Forecast Period |
2024-2031 |
|
Data Availability |
Value (US$) and Volume (Tons) |
|
Segments Covered |
Product, Route of Administration, Animal, Application and Distribution Channel |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For More Insights about the Market Request Free Sample
Market Dynamics
The increasing launch and FDA Approvals by the key market players are the factors to drive the market growth.
On September 27, 2022, Zoetis launched Solensia to manage feline osteoarthritis pain in the United States. Furthermore, on January 20, 2022, the U.S. Food and Drug Administration approved Zorbium (buprenorphine transdermal solution), the first transdermal buprenorphine animal drug intended to control pain in cats after surgery. Thus, from the above factors, the market is expected to drive in the forecast period.
Side effects associated with treatment are expected to hamper the market growth.
The side effects like vomiting, diarrhea, stomach ulcers, skin irritation, depression, and restlessness associated with the use of Veterinary drugs are making animal owners reluctant to put their pets under medication. Therefore, the side effects on animals from the use of veterinary drugs can restrain the market during the forecast period.
Segmentation Analysis
The united states veterinary pain management market is segmented based on product, route of administration, animal, application, and distribution Channel.
The device segment will be dominated as market players adopt and implement various strategies such as product launches, collaborations, expansions, and mergers.
The increase can be attributed to factors such as rising pet adoption and rising per capita animal healthcare expenditure in the region. The increase in the prevalence of various animal diseases and injuries has been identified as the primary factor driving market growth.
Laser therapy is used to treat chronic and acute injuries, arthritis, sprains and strains, swelling caused by back disc problems, and muscular-skeletal abnormalities. It also aids in the regeneration of nerve tissue after surgery. The most common laser therapy is the therapeutic laser treatment of osteoarthritis (OA) in dogs and cats. In osteoarthritis (OA), the laser intensity should be between 8 and 10 J/cm2. Moreover, due to the inflammation associated with the disease, laser therapy may help with tendonitis. By varying the level of emission, some laser devices can be used for both surgical and therapeutic purposes. Laser therapy brands for veterinary pain management include B-Cure Laser, TENDLITE, Lumasoothe, iReliev, Keebomed, and MLS Laser Therapy (ASAveterinary).
In addition, in October 2021, Summus Laser introduced the "Horizon Veterinary Laser System," a Class IV laser therapy system designed specifically for veterinary pain management. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.
Source: DataM Intelligence Analysis (2023)
Market Key Players
The major united states players include Assisi Animal Health, Ceva, Zoetis, Elanco, Iroko Pharmaceuticals, Boehringer Ingelheim and Vetoquinol S.A.
Key Developments
- On August 4, 2021, Zoetis acquired Jurox, a Leading Provider and Manufacturer of Livestock and Companion Animal Products
- On April 8, 2020, Ceva Sante Animale launched the cattle pain campaign to raise awareness about the importance of pain relief in lame cattle.
The united states veterinary pain management market report would provide approximately 38 tables, 35 figures, and 195 Pages.
